183 related articles for article (PubMed ID: 36232400)
1. Evaluation of the Sensitivity of Breast Cancer Cell Lines to Cardiac Glycosides Unveils ATP1B3 as a Possible Biomarker for the Personalized Treatment of ERα Expressing Breast Cancers.
Acconcia F
Int J Mol Sci; 2022 Sep; 23(19):. PubMed ID: 36232400
[TBL] [Abstract][Full Text] [Related]
2. Clinically relevant CHK1 inhibitors abrogate wild-type and Y537S mutant ERα expression and proliferation in luminal primary and metastatic breast cancer cells.
Pescatori S; Leone S; Cipolletti M; Bartoloni S; di Masi A; Acconcia F
J Exp Clin Cancer Res; 2022 Apr; 41(1):141. PubMed ID: 35418303
[TBL] [Abstract][Full Text] [Related]
3. In silico screening for ERα down modulators identifies thioridazine as an anti-proliferative agent in primary, 4OH-tamoxifen-resistant and Y537S ERα-expressing breast cancer cells.
Busonero C; Leone S; Bianchi F; Acconcia F
Cell Oncol (Dordr); 2018 Dec; 41(6):677-686. PubMed ID: 30182339
[TBL] [Abstract][Full Text] [Related]
4. VAV3 mediates resistance to breast cancer endocrine therapy.
Aguilar H; Urruticoechea A; Halonen P; Kiyotani K; Mushiroda T; Barril X; Serra-Musach J; Islam A; Caizzi L; Di Croce L; Nevedomskaya E; Zwart W; Bostner J; Karlsson E; Pérez Tenorio G; Fornander T; Sgroi DC; Garcia-Mata R; Jansen MP; García N; Bonifaci N; Climent F; Soler MT; Rodríguez-Vida A; Gil M; Brunet J; Martrat G; Gómez-Baldó L; Extremera AI; Figueras A; Balart J; Clarke R; Burnstein KL; Carlson KE; Katzenellenbogen JA; Vizoso M; Esteller M; Villanueva A; Rodríguez-Peña AB; Bustelo XR; Nakamura Y; Zembutsu H; Stål O; Beijersbergen RL; Pujana MA
Breast Cancer Res; 2014 May; 16(3):R53. PubMed ID: 24886537
[TBL] [Abstract][Full Text] [Related]
5. Differential effects of aromatase inhibitors and antiestrogens on estrogen receptor expression in breast cancer cells.
Smollich M; Götte M; Fischgräbe J; Radke I; Kiesel L; Wülfing P
Anticancer Res; 2009 Jun; 29(6):2167-71. PubMed ID: 19528477
[TBL] [Abstract][Full Text] [Related]
6. Protein kinase D1 regulates ERα-positive breast cancer cell growth response to 17β-estradiol and contributes to poor prognosis in patients.
Karam M; Bièche I; Legay C; Vacher S; Auclair C; Ricort JM
J Cell Mol Med; 2014 Dec; 18(12):2536-52. PubMed ID: 25287328
[TBL] [Abstract][Full Text] [Related]
7. Expression of estrogen-related gene markers in breast cancer tissue predicts aromatase inhibitor responsiveness.
Moy I; Lin Z; Rademaker AW; Reierstad S; Khan SA; Bulun SE
PLoS One; 2013; 8(11):e77543. PubMed ID: 24223121
[TBL] [Abstract][Full Text] [Related]
8. A functional drug re-purposing screening identifies carfilzomib as a drug preventing 17β-estradiol: ERα signaling and cell proliferation in breast cancer cells.
Busonero C; Leone S; Klemm C; Acconcia F
Mol Cell Endocrinol; 2018 Jan; 460():229-237. PubMed ID: 28760601
[TBL] [Abstract][Full Text] [Related]
9. A functional genetic screen for metabolic proteins unveils GART and the
Cipolletti M; Leone S; Bartoloni S; Acconcia F
Front Endocrinol (Lausanne); 2023; 14():1129162. PubMed ID: 37143728
[TBL] [Abstract][Full Text] [Related]
10. AR collaborates with ERα in aromatase inhibitor-resistant breast cancer.
Rechoum Y; Rovito D; Iacopetta D; Barone I; Andò S; Weigel NL; O'Malley BW; Brown PH; Fuqua SA
Breast Cancer Res Treat; 2014 Oct; 147(3):473-85. PubMed ID: 25178514
[TBL] [Abstract][Full Text] [Related]
11. Estrogen utilization of IGF-1-R and EGF-R to signal in breast cancer cells.
Song RX; Chen Y; Zhang Z; Bao Y; Yue W; Wang JP; Fan P; Santen RJ
J Steroid Biochem Mol Biol; 2010 Feb; 118(4-5):219-30. PubMed ID: 19815064
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of a novel orally active SERD AZD9496 against hormone dependent post-menopausal breast cancer depends on inhibition of cellular aromatase activity.
Kazi A; Goloubeva O; Schech A; Yu S; Sabnis GJ
J Steroid Biochem Mol Biol; 2020 Sep; 202():105697. PubMed ID: 32461092
[TBL] [Abstract][Full Text] [Related]
13. Strategies to degrade estrogen receptor α in primary and ESR1 mutant-expressing metastatic breast cancer.
Busonero C; Leone S; Bartoloni S; Acconcia F
Mol Cell Endocrinol; 2019 Jan; 480():107-121. PubMed ID: 30389467
[TBL] [Abstract][Full Text] [Related]
14. Targeting tumour re-wiring by triple blockade of mTORC1, epidermal growth factor, and oestrogen receptor signalling pathways in endocrine-resistant breast cancer.
Ribas R; Pancholi S; Rani A; Schuster E; Guest SK; Nikitorowicz-Buniak J; Simigdala N; Thornhill A; Avogadri-Connors F; Cutler RE; Lalani AS; Dowsett M; Johnston SR; Martin LA
Breast Cancer Res; 2018 Jun; 20(1):44. PubMed ID: 29880014
[TBL] [Abstract][Full Text] [Related]
15. Epidermal growth factor receptor signalling in human breast cancer cells operates parallel to estrogen receptor α signalling and results in tamoxifen insensitive proliferation.
Moerkens M; Zhang Y; Wester L; van de Water B; Meerman JH
BMC Cancer; 2014 Apr; 14():283. PubMed ID: 24758408
[TBL] [Abstract][Full Text] [Related]
16. Fulvestrant inhibits growth of triple negative breast cancer and synergizes with tamoxifen in ERα positive breast cancer by up-regulation of ERβ.
Mishra AK; Abrahamsson A; Dabrosin C
Oncotarget; 2016 Aug; 7(35):56876-56888. PubMed ID: 27486755
[TBL] [Abstract][Full Text] [Related]
17. New cell culture model for aromatase inhibitor-resistant breast cancer shows sensitivity to fulvestrant treatment and cross-resistance between letrozole and exemestane.
Hole S; Pedersen AM; Hansen SK; Lundqvist J; Yde CW; Lykkesfeldt AE
Int J Oncol; 2015 Apr; 46(4):1481-90. PubMed ID: 25625755
[TBL] [Abstract][Full Text] [Related]
18. Antiestrogens in combination with immune checkpoint inhibitors in breast cancer immunotherapy.
Márquez-Garbán DC; Deng G; Comin-Anduix B; Garcia AJ; Xing Y; Chen HW; Cheung-Lau G; Hamilton N; Jung ME; Pietras RJ
J Steroid Biochem Mol Biol; 2019 Oct; 193():105415. PubMed ID: 31226312
[TBL] [Abstract][Full Text] [Related]
19. Sodium/potassium ATPase (Na+, K+-ATPase) and ouabain/related cardiac glycosides: A new paradigm for development of anti- breast cancer drugs?
Chen JQ; Contreras RG; Wang R; Fernandez SV; Shoshani L; Russo IH; Cereijido M; Russo J
Breast Cancer Res Treat; 2006 Mar; 96(1):1-15. PubMed ID: 16322895
[TBL] [Abstract][Full Text] [Related]
20. Unexpected Impact of a Hepatitis C Virus Inhibitor on 17β-Estradiol Signaling in Breast Cancer.
Bartoloni S; Leone S; Acconcia F
Int J Mol Sci; 2020 May; 21(10):. PubMed ID: 32408555
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
